Erythropoietin Stimulating Agents Market By Products (Epoetin-Alfa, Epoetin-Beta, Darbepoetin-Alfa), By Application (Cancer Treatment, Hiv Treatment, Kidney Disorder) , Industry Size, Growth, Share And Forecast To 2022
Key Findings
The global erythropoietin stimulating agents market is expected to grow at the CAGR of 0.3% during 2015-2022, and it is expected to reach $7.4 billion by 2022. An erythropoiesis stimulating agent is a medicine similar to erythropoietin which stimulates red blood cell production. ESA, structurally and biologically similar to naturally occurring protein erythropoietin. These type of agents are used in conditions where there is reduced blood production in the body which causes anemia such as HIV, cancer, chronic kidney diseases. The bio similar of Erythropoietin drugs also entered into the market. Availability of numerous bio similar has rendered low cost option to the patients, therefore increased adoption rates for EPO drugs particularly in the developing regions. Apart from this increasing awareness about the benefits of Erythropoietin drugs also enhances this market.
Market Segment Insight
The global erythropoietin stimulating agent’s products, application and regional outlook. In products the market is segmented into Epoetin Alfa, Epoetin Beta, and Darbepoetin Alfa. Amongst all synthetic erythropoietin products, Epoetin Alfa and it’s one more version Darbepoetin Alfa, are the most popular drugs. Epoetin Alfa and Darbepoeitin Alfa collectively accounted for about 80% of total EPO drugs market revenue. Amgen Inc. was the first company to innovate and patent Epoetin Alfa and Darbepoeitin Alfa. The reason for the success of these two drugs is the therapeutic effect and cheaply priced nature.In terms of application market is divided into cancer treatments, HIV treatments, kidney disorder and others, the treatment of all this diseases causes anemia, and erythropoietin stimulating agents are used to treat anemic patients as erythropoietin is a glycoprotein which is a hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis. The global erythropoietin stimulating agents market is divided geographically by North America, Europe, Asia pacific and rest of the world. Europe is the global leader in erythropoietin stimulating agents market the main reason to fueling up this market in Europe is due to rise in anemic patients due treatment of major disease like cancer, HIV and kidney diseases, apart from that stringent government policies towards use of cheap and effective drugs also carries the Europe market up, speedy regulatory approvals for EPO drugs also forces the global erythropoietin stimulating agent market in Europe region. Asia pacific and North America is the fastest growing market and global players Amgen Inc. , Hoffmann la Roche and Johnson and Johnson is finding this two market a revenue earning and profitable market. The major growth and developing factors in this two market is due to rise in HIV, Cancer and kidney disease patients, government’s policies towards use of erythropoietin stimulating drugs, and quality of infrastructure for manufacturers.The adoption rate of erythropoietin stimulating drugs is slow as a result this market is having a least share in global erythropoietin drugs market.
Regional Insight
The global erythropoietin stimulating agents marketis divided into North America, Europe, Asia Pacific and Rest of the World.Europe is global leader of erythropoietin stimulating agents market due to favorable reimbursement policies and regulatory approvals for EPO drugs. Rise in chronic diseases like kidney failure, HIV and cancer are also enhancing the Europe market as rising number of anemic patients increases due to chemotherapy used in treatment of such diseases, rising technological advancement also plays a driving factor in making Europe a leader in global Erythropoietin market. Asia pacific and North America are the fastest growing markets in forecast year. The reason for rising Asia Pacific market is rise in population and increase in geriatric population numbers, government’s regulations towards use of bio similar drugs also enhances the Asia pacific market, the reason for North America market growth is due to technological advancement in medical field, rise in chronic diseases patients numbers as per the survey the U.S is expected to see a good increase in the number of chronic disease patients in near future, due to rise in chronic diseases, anemic patients are likely to increase which directly affects the global erythropoietin stimulating agents market. Rest of the world is having the least number of market share then other geography, but it’s expected to rise in rest of the world market also due to high commercialization of EPO drugs and governments policies to use bio similar products.
Competitive Insights
Some of the keymarket players are3SBio, Amgen Inc.Biocon, BioSidus, Celltrion, Inc. Dr. Reddy’s Laboratories, Intas Pharmaceuticals, Johnson and Johnsons etc. Acquisitions, new product development, collaborations, joint ventures, mergers and expansions are the key strategies adopted by the market players to sustain in the market. Bayer and BioNTech join forces to develop innovative products in near future. In July 2015 3SBio acquired Zhejiang Wansheng Pharmaceutical
CHAP 1. METHODOLOGY & SCOPE 13
1.1. RESEARCH METHODOLOGY 13
1.2. RESEARCH SCOPE & ASSUMPTIONS 13
1.3. LIST OF DATA SOURCES 13
CHAP 2. EXECUTIVE SUMMARY 14
2.1. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET SUMMARY & KEY BUYING CRITERIA 14
2.2. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET OUTLOOK 14
2.3. MARKET SEGMENTATION ANALYSIS 14
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 14
2.5. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET VALUE CHAIN ANALYSIS 14
2.6. VENDOR LANDSCAPE 14
CHAP 3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET 15
3.1. MARKET DRIVER ANALYSIS 15
3.1.1. INCREASING LEVEL OF AWARENESS ABOUT THE BENEFITS OF EOP THERAPIES 15
3.1.2. INCREASING NUMBER OF CASES INCLUDING CANCER, HIV, KIDNEY DISEASES 15
3.1.3. GROWING TRENDS OF COMMERCIALIZATION FOR ERYTHROPOIETIN BIOSIMILARS 15
3.2. MARKET RESTRAINT ANALYSIS 15
3.2.1. LONGER DURATION OF TREATMENT 15
3.2.2. ADVERSE AMOUNT OF SIDE EFFECTS 15
3.3. KEY OPPORTUNITIES 15
3.3.1. COMMERCIALIZATION OF DARBEPOTIN ALFA BIOSIMILAR 15
3.3.2. ACHIEVING ECONOMIES OF SCALE ACROSS DEVELOPED REGION WITH BIOSIMILAR VERSION OF EPO 15
3.4. CHALLENGES 15
3.4.1. LACK OF AWARENESS OF EOP IN EMERGING COUNTRIES 15
3.4.2. CONSUMER MANUFACTURERS GAP 15
CHAP 4. INDUSTRY ANALYSIS 16
4.1. GLOBAL ABLATION TECHNOLOGIE SMARKET– PORTER’S FIVE FORCE MODEL 16
4.2. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET – PESTEL ANALYSIS 16
4.3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET – GAP ANALYSIS 16
CHAP 5. GLOBAL RENAL DISEASES TREATMENTS TECHNOLOGIES MARKET BY PRODUCTS 2012-2022 ($ BILLION) 17
5.1. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY EPOETIN-ALFA 2012-2022 ($ BILLION) 17
5.2. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY EPOETIN-BETA 2012-2022 ($ BILLION) 17
5.3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY DARBEPOETIN-ALFA 2012-2022 ($ BILLION) 17
CHAP 6. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY APPLICATION 2012-2022 ($ BILLION) 18
6.1. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY CANCER TREATMENT 2012-2022 ($ BILLION) 18
6.2. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY HIV TREATMENT 2012-2022 ($ BILLION) 18
6.3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY KIDNEY DISORDER 2012-2022 ($ BILLION) 18
6.4. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY OTHERS 2012-2022 ($ BILLION) 18
CHAP 7. GLOBAL ABLATION TECHNOLOGIES MARKET, REGIONAL OUTLOOK 2012-2022 ($ BILLION) 19
7.1. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY REGION 2012-2022 ($ BILLION) 19
7.2. NORTH AMERICA 19
7.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 19
7.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 19
7.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 19
7.2.3.1. U.S. 19
7.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 19
7.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 19
7.2.3.2. CANADA 19
7.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 19
7.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 19
7.3. EUROPE 20
7.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
7.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 20
7.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
7.3.3.1. GERMANY 20
7.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
7.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
7.3.3.2. UK 20
7.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
7.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
7.3.3.3. FRANCE 20
7.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
7.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
7.3.3.4. ITALY 20
7.3.3.4.1. ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
7.3.3.4.2. ITALY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
7.3.3.5. SPAIN 20
7.3.3.5.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
7.3.3.5.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
7.3.3.6. REST OF EUROPE 21
7.3.3.6.1. REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 21
7.3.3.6.2. REST OF EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 21
7.4. ASIA PACIFIC 21
7.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
7.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 21
7.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
7.4.3.1. CHINA 21
7.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
7.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
7.4.3.2. INDIA 21
7.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
7.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
7.4.3.3. JAPAN 21
7.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
7.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 21
7.4.3.4. SOUTH KOREA 21
7.4.3.4.1. SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
7.4.3.4.2. SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 22
7.4.3.5. REST OF APAC 22
7.4.3.5.1. REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
7.4.3.5.2. REST OF APAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
7.5. REST OF THE WORLD 22
7.5.1. REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
7.5.2. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 22
7.5.3. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
7.5.3.1. LATIN AMERICA 22
7.5.3.1.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
7.5.3.1.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
7.5.3.2. MIDDLE EAST AND AFRICA 22
7.5.3.2.1. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
7.5.3.2.2. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
CHAP 8. COMPETITIVE LANDSCAPE 23
8.1. 3SBIO 24
8.1.1. COMPANY OVERVIEW 24
8.1.2. SCOT ANALYSIS 24
8.1.3. PRODUCT BENCHMARKING 24
8.1.4. STRATEGIC INITIATIVES 24
8.2. AMGEN INC. 24
8.2.1. COMPANY OVERVIEW 24
8.2.2. SCOT ANALYSIS 24
8.2.3. PRODUCT BENCHMARKING 24
8.2.4. STRATEGIC INITIATIVES 24
8.3. BIOCON 24
8.3.1. COMPANY OVERVIEW 24
8.3.2. SCOT ANALYSIS 24
8.3.3. PRODUCT BENCHMARKING 24
8.3.4. STRATEGIC INITIATIVES 24
8.4. BIOSIDUS 24
8.4.1. SCOT ANALYSIS 24
8.4.2. PRODUCT BENCHMARKING 24
8.4.3. STRATEGIC INITIATIVES 24
8.5. CELLTRION, INC 24
8.5.1. COMPANY OVERVIEW 24
8.5.2. SCOT ANALYSIS 24
8.5.3. PRODUCT BENCHMARKING 24
8.5.4. STRATEGIC INITIATIVES 24
8.6. DR. REDDY'S LABORATORIES. 24
8.6.1. COMPANY OVERVIEW 24
8.6.2. SCOT ANALYSIS 24
8.6.3. PRODUCT BENCHMARKING 25
8.6.4. STRATEGIC INITIATIVES 25
8.7. HOFFMANN-LA ROCHE 25
8.7.1. COMPANY OVERVIEW 25
8.7.2. SCOT ANALYSIS 25
8.7.3. PRODUCT BENCHMARKING 25
8.7.4. STRATEGIC INITIATIVES 25
8.8. INTAS PHARMACEUTICALS 25
8.8.1. COMPANY OVERVIEW 25
8.8.2. SCOT ANALYSIS 25
8.8.3. PRODUCT BENCHMARKING 25
8.8.4. STRATEGIC INITIATIVES 25
8.9. JOHNSON AND JOHNSON 25
8.9.1. COMPANY OVERVIEW 25
8.9.2. SCOT ANALYSIS 25
8.9.3. PRODUCT BENCHMARKING 25
8.9.4. STRATEGIC INITIATIVES 25
8.10. LG LIFE SCIENCES LTD. 25
8.10.1. COMPANY OVERVIEW 25
8.10.2. SCOT ANALYSIS 25
8.10.3. PRODUCT BENCHMARKING 25
8.10.4. STRATEGIC INITIATIVES 25
8.11. RANBAXY LABORATORIES LTD. 25
8.11.1. COMPANY OVERVIEW 25
8.11.2. SCOT ANALYSIS 25
8.11.3. PRODUCT BENCHMARKING 25
8.11.4. STRATEGIC INITIATIVES 25
8.12. ROCHE 26
8.12.1. COMPANY OVERVIEW 26
8.12.2. SCOT ANALYSIS 26
8.12.3. PRODUCT BENCHMARKING 26
8.12.4. STRATEGIC INITIATIVES 26
8.13. RPG LIFE SCIENCES 26
8.13.1. COMPANY OVERVIEW 26
8.13.2. SCOT ANALYSIS 26
8.13.3. PRODUCT BENCHMARKING 26
8.13.4. STRATEGIC INITIATIVES 26
8.14. SANDOZ HOSPIRA 26
8.14.1. COMPANY OVERVIEW 26
8.14.2. SCOT ANALYSIS 26
8.14.3. PRODUCT BENCHMARKING 26
8.14.4. STRATEGIC INITIATIVES 26
8.15. TEVA PHARMACEUTICAL INDUSTRIES LTD. 26
8.15.1. COMPANY OVERVIEW 26
8.15.2. SCOT ANALYSIS 26
8.15.3. PRODUCT BENCHMARKING 26
8.15.4. STRATEGIC INITIATIVES 26
TABLE 1 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY PRODUCTS 2012-2022 ($ BILLION) 26
TABLE 2 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY EPOETIN-ALFA 2012-2022 ($ BILLION) 26
TABLE 3 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY EPOETIN-BETA 2012-2022 ($ BILLION) 26
TABLE 4 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY DARBEPOETIN-ALFA 2012-2022 ($ BILLION) 27
TABLE 5 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY APPLICATION 2012-2022 ($ BILLION) 27
TABLE 6 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY CANCER TREATMENT 2012-2022 ($ BILLION) 27
TABLE 7 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY HIV TREATMENT 2012-2022 ($ BILLION) 27
TABLE 8 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY KIDNEY DISORDER 2012-2022 ($ BILLION) 27
TABLE 9 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY OTHERS 2012-2022 ($ BILLION) 27
TABLE 10 GLOBAL ABLATION TECHNOLOGIES MARKET, REGIONAL OUTLOOK 2012-2022 ($ BILLION) 27
TABLE 11 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET BY REGION 2012-2022 ($ BILLION) 27
TABLE 12 NORTH AMERICA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
TABLE 13 NORTH AMERICA MARKETESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 27
TABLE 14 NORTH AMERICA MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
TABLE 15 U.S. MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
TABLE 16 U.S. MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
TABLE 17 CANADA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
TABLE 18 CANADA MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
TABLE 19 EUROPE MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
TABLE 20 EUROPE MARKETESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 27
TABLE 21 EUROPE MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
TABLE 22 GERMANY MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
TABLE 23 GERMANY MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
TABLE 24 UK MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
TABLE 25 UK MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
TABLE 26 FRANCE MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
TABLE 27 FRANCE MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
TABLE 28 ITALY MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
TABLE 29 ITALY MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
TABLE 30 SPAIN MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
TABLE 31 SPAIN MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
TABLE 32 28
TABLE 33 REST OF EUROPE MARKETESTIMATES AND FORECAST2012-2022($BILLION) 28
TABLE 34 REST OF EUROPE MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 28
TABLE 35 ASIA PACIFIC MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
TABLE 36 ASIA PACIFIC MARKETESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 28
TABLE 37 ASIA PACIFIC MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
TABLE 38 CHINA 28
TABLE 39 CHINA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
TABLE 40 CHINA MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
TABLE 41 INDIA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
TABLE 42 INDIA MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
TABLE 43 JAPAN MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
TABLE 44 JAPAN MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 29
TABLE 45 SOUTH KOREA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
TABLE 46 SOUTH KOREA MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 29
TABLE 47 REST OF APAC MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
TABLE 48 REST OF APAC MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
TABLE 49 REST OF THE WORLD MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
TABLE 50 REST OF THE WORLD MARKETESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 29
TABLE 51 REST OF THE WORLD MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
TABLE 52 LATIN AMERICA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
TABLE 53 LATIN AMERICA MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
TABLE 54 MIDDLE EAST AND AFRICA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
TABLE 55 MIDDLE EAST AND AFRICA MARKETESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
FIGURE 1 NORTH AMERICA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 2 U.S. MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 3 CANADA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 4 EUROPE MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 5 GERMANY MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 6 UK MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 7 FRANCE MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 8 ITALY MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 9 SPAIN MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 10 REST OF EUROPE MARKETESTIMATES AND FORECAST2012-2022($BILLION) 30
FIGURE 11 ASIA PACIFIC MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 12 CHINA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 13 INDIA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 14 JAPAN MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 15 SOUTH KOREA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
FIGURE 16 REST OF APAC MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 17 REST OF THE WORLD MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 18 LATIN AMERICA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 19 MIDDLE EAST AND AFRICA MARKETESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)